Lijnen H R, Dewerchin M, De Cock F, Collen D
Center for Thrombosis and Vascular Research, University of Leuven, Belgium.
Thromb Res. 1990 Feb 1;57(3):333-42. doi: 10.1016/0049-3848(90)90249-c.
The effect of fibrin-targeting of urokinase-type plasminogen activator (u-PA) on its fibrinolytic potency was studied using recombinant fusion proteins of u-PA with the NH2-terminal region of tissue-type plasminogen activator (t-PA/u-PA) and chemical complexes of u-PA with F(ab')2 fragments of a fibrin specific monoclonal antibody (u-PA/MA-15C5-F(ab')2). Two chain derivatives of a low Mr variant of u-PA comprising amino acids Leu144-Leu411 (tcu-PA-32k), obtained by cleavage of recombinant single-chain u-PA (rscu-PA-32k) with thrombin (rtcu-PA-32k/T) or plasmin (rtcu-PA-32k/P) were investigated. The plasmin-derived two chain u-PA moieties, rtcu-PA-32k/P, rt-PA/tcu-PA-32k/P and rtcu-PA-32k/MA-15C5-F(ab')2/P had high specific activities in amidolytic and fibrin plate assays (130,000 and 150,000 IU/mg u-PA, 43,000 and 71,000 IU/mg u-PA and 32,000 and 56,000 IU/mg u-PA respectively). The thrombin-derived two chain u-PA moieties had a very low amidolytic activity, corresponding to less than or equal to 1 percent of that of their plasmin-derived counterparts. On fibrin plates, however, rtcu-PA-32k/T had a negligible activity, whereas rt-PA/tcu-PA-32k/T and rtcu-PA-32k/MA-15C5-F(ab')2/T had specific activities of 12,000 and 25,000 IU/mg u-PA respectively. The catalytic efficiency for plasminogen activation of rtcu-PA-32k/MA-15C5-F(ab')2/T is 4,000-fold lower than that of rtcu-PA-32k/MA-15C5-F(ab')2/P, but its concentration required for 50 percent lysis in 2 hours of a 125I-fibrin labeled plasma clot in human plasma (C50) is only 25-fold higher. The catalytic efficiency of rt-PA/tcu-PA-32k/T is 1,600-fold lower and the C50 100-fold higher than that of rt-PA/tcu-PA-32k/P. The catalytic efficiency and the fibrinolytic potential of rtcu-PA-32k/T are negligible as compared to that of rtcu-PA-32k/P. These observations may be explained by conversion of the thrombin derived two chain u-PA moieties to their plasmin-derived analogues at the fibrin surface. This conversion appears to be most efficient for the antibody conjugate which has a high fibrin-affinity, less efficient for the t-PA/u-PA chimera which has only moderate fibrin-affinity, and negligible for the unconjugated u-PA moiety which has no fibrin-affinity. These findings illustrate the importance of plasmin-mediated positive feedback mechanisms in u-PA mediated clot lysis.
利用组织型纤溶酶原激活剂(t-PA)氨基末端区域与尿激酶型纤溶酶原激活剂(u-PA)的重组融合蛋白以及u-PA与纤维蛋白特异性单克隆抗体F(ab')2片段的化学复合物(u-PA/MA-15C5-F(ab')2),研究了u-PA靶向纤维蛋白对其纤溶效力的影响。研究了通过用凝血酶(rtcu-PA-32k/T)或纤溶酶(rtcu-PA-32k/P)切割重组单链u-PA(rscu-PA-32k)获得的u-PA低分子量变体的双链衍生物,其包含氨基酸Leu144-Leu411(tcu-PA-32k)。纤溶酶衍生的双链u-PA部分,rtcu-PA-32k/P、rt-PA/tcu-PA-32k/P和rtcu-PA-32k/MA-15C5-F(ab')2/P在酰胺水解和纤维蛋白平板试验中具有高比活性(分别为130,000和150,000 IU/mg u-PA、43,000和71,000 IU/mg u-PA以及32,000和56,000 IU/mg u-PA)。凝血酶衍生的双链u-PA部分具有非常低的酰胺水解活性,相当于其纤溶酶衍生对应物的小于或等于1%。然而,在纤维蛋白平板上,rtcu-PA-32k/T的活性可忽略不计,而rt-PA/tcu-PA-32k/T和rtcu-PA-32k/MA-15C5-F(ab')2/T的比活性分别为12,000和25,000 IU/mg u-PA。rtcu-PA-32k/MA-15C5-F(ab')2/T对纤溶酶原激活的催化效率比rtcu-PA-32k/MA-15C5-F(ab')2/P低4000倍,但其在人血浆中2小时内使125I-纤维蛋白标记血浆凝块50%溶解所需的浓度(C50)仅高25倍。rt-PA/tcu-PA-32k/T的催化效率比rt-PA/tcu-PA-32k/P低1600倍,C50高100倍。与rtcu-PA-32k/P相比,rtcu-PA-32k/T的催化效率和纤溶潜力可忽略不计。这些观察结果可能是由于凝血酶衍生的双链u-PA部分在纤维蛋白表面转化为其纤溶酶衍生的类似物所致。这种转化似乎对具有高纤维蛋白亲和力的抗体偶联物最有效,对具有中等纤维蛋白亲和力的t-PA/u-PA嵌合体效率较低,而对没有纤维蛋白亲和力的未偶联u-PA部分可忽略不计。这些发现说明了纤溶酶介导的正反馈机制在u-PA介导的凝块溶解中的重要性。